Revive Therapeutics Gains 25% on Positive FDA Comments.
The Company stated yesterday that it "has received positive comments from the FDA in regard to the Company’s request to determine and agree on...
Could Bucillamine be the Key to Preventing Lockdowns in Places Like North Korea?
Revive Therapeutics Nears FDA-EUA Approval or Non-approval, for Bucillamine its Novel Anti-inflammatory and Antioxidant. Bucillamine 'Boosts' Glutathione, a Natural Substance Found in Virtually all...
Smart for Life (SMFL) Teams up With Diamond Creek Capital
IPO Buyers Liked it at $5.00. We Liked it at $0.85. We Love it at $0.55.
LIVE QUOTE
Smart for Life (SMFL) teams up with Diamond...
Video Interview: Smart for Life (SMFL) CEO A.J. Cervantes.
Excellent interview. We were at the Noble Investor Conference to see it live. And we were at the manufacturing plant this Friday. We've worked...
New Report: Lion Group Holdings (LGHL) Initiating Coverage. $1.07
Massive Long-Term Potential from Singapore based Rising Fintech Star.
A Fintech that nearly 'has it all' reported impressive (up 164% to $27 million) record numbers...
Report on Citius Pharma (CTXR): North Shore Research Issues a $10 Price Target, a...
We're Up 181% on Citius Pharma (CTXR), Despite its Being Well Below it's Recent High of $4.30. We Now Have Two $10 Price Targets....
Smart For Life to Present at The Noble Capital Markets Eighteenth Annual Investor Conference.
MIAMI, April 14, 2022 (GLOBE NEWSWIRE) -- Smart for Life, Inc. (Nasdaq: SMFL) (“Smart for Life” or the “Company”), a global leading developer, marketer,...
Revive Therapeutics (RVVTF) Moves a Step Closer to FDA Verdict for Its Novel Covid...
Two Binary Events Directly Ahead.
As in Months Away, not Years. Share Price up 76% During April.
As we stated earlier, Revive Therapeutics (RVVTF)...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
TORONTO, April 11, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company...
Report on Mitesco (MITI): Zacks Issues $0.53 Price Target, a 165% Potential Gain.
LIVE QUOTE
Original Report: Initiating Coverage on Mitesco (MITI) FKA True Nature Holdings (TNTY) $0.02. Adding to Watch List.
Mitesco, Inc. (MITI) is building a better...